Article Sidebar

Submitted
5 April 2018
Accepted
5 April 2018
Published
5 April 2018
Download
PDF
Statistic
Read Counter : 1121 Download : 887

Main Article Content

Abstract

Mammary Serine Protease Inhibitor (maspin) is a tumor suppressor gene, a member of the serine protease inhibitor (serpin) family that works by inhibiting motility of cell movement, invasion and metastasis. Maspin expression is expected to be a prognostic factor as well as a predictive factor in mammary tumors. However, in some recent studies, maspin has a variety of expressions. Although it is known that no maspine appears as an indicator of tumor progression and metastasis, recent study has shown that maspine expression is associated with an aggressive phenotype of breast cancer and with a poor prognosis. Correlations between maspine expression and poor prognosis have also been reported in pancreatic, ovarian, thyroid, bladder and lung cancers. Knowledge of the expression and role of this maspin as well as its relationship with the pathogenesis of breast invasive ductal carcinoma is still small. The aim of this study was to look at differences in maspin expression in breast-invasive ductal carcinoma of stage IIA and stage IIIB groups. This research method used analytic observational research with cross sectional approach. The samples were invasive carcinoma of NST paraffin at the Department of Anatomic Pathology of Dr Soetomo Hospital, Surabaya, from January to December 2015. Thirty samples were divided into two groups, namely stage IIA and stage IIIB groups and immunohistochemical examination with maspin antibody was carried out. The difference of maspin expression in stage IIA and stage IIIB was analyzed using Mann-Whitney statistic test. There were significant differences in maspin expression between stage IIA and stage IIIB groups, where stage IIA has a high maspin expression rather than stage IIIB.

Keywords

Invasive breast cancer stages IIA and IIIB maspin

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Hardika, A. S., & Fauziah, D. (2018). Analysis of Maspin Expression in Invasive Ductal Carcinoma of the Breast on Stages IIA and IIIB. Folia Medica Indonesiana, 54(1), 6–9. https://doi.org/10.20473/fmi.v54i1.8043
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Berardi R, Morgese F, Onofri A, Mazzanti P, Pistelly M, et al (2013). Role of maspin in cancer. Clinical and Translational Medicine 2, 8
  2. Bodenstine TM, Seftore RE, Khalkhali-Ellis Z, Seftor EA, Pemberton PA, Hendrix MJ (2012). Maspin: molecular mechanisms and therapeutic implications. Cancer Metastasis Rev 31, 529-51
  3. Jiang N, Meng Y, Zhang S, Osman E, Sheng S (2002). Maspin Sensitizes Breast Carcinoma Cells to Induced Apoptosis. Oncogene 21, 4089-4098
  4. Lee MJ, Suh CH, Li Zh (2006). Clinicopathological significance of maspin in breast cancer. J Korean Med Sci 21, 309-14
  5. Maass N, Hojo T, Zhang M, Sager M, Jonat R, Nagasaki K (2000). Maspin-A novel protease inhibitor with tumor-suppressing activity in breast cancer. Review Article, Octa Oncologica, 186
  6. Maass N, Teffner M, Rosel F, Pawaresch R, Jonat W, Nagasaki K (2001). Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. Journal of pathology 195, 321-326
  7. Stark AM, Christian S, Maass N, Hugo HH, Jonat W, Mehdorn M, Held Feindt (2010). Expression of metastasis suppressor gene maspin is reduced in breast cancer brain metastasis and correlates with the estrogen receptor status. Neurological research 32
  8. Streuli CH (2002). Commentary: maspin is a tumor suppressor that inhibits breast cancer tumours metastasis in vivo. Breast Cancer Research 4, 137-140
  9. Umekita Y, Ohi Y, Sagara Y, Yoshida H (2002). Expression of maspin predicts poor prognosis in breast cancer patients. Int. J. Cancer 100, 452-455
  10. Umekita Y, Ohi Y, Souda M, Rai Y, SagaraY, Sagara Y, Tamada S, Tanimoto A (2011). Maspin expression is frequent and correlates with basal markers in triple negative breast cancer. Diagnostic Pathology 6, 36
  11. Umekita Y, Yoshida H (2003). Expression of maspin is up regulated during the progression of mammary ductal carcinoma. Department of Pathology, faculty of medicine, Kagoshima University, Histopatology 42, 541-545